Skip to content
Screener

AnaptysBio, Inc. ANAB Internal Expenses — General And Administrative Expense

Other product segments

External Expenses
$12.12M+119%

Similar metrics at other companies

TRA
TRAXExternal Expenses — General And Administrative Expense
$8.72M+127%
Solid Biosciences Inc. logo
SLDBInternal General And Administrative Expense — General And Administrative Expense
$4.73M+40.9%
TRA
TRAXInternal Expense — General And Administrative Expense
$10.14M+69.9%
Beam Therapeutics logo
BEAMExternal General And Administrative Expenses — General And Administrative Expense
$13.37M+149%
Solid Biosciences Inc. logo
SLDBExternal General And Administrative Expense — General And Administrative Expense
$6.33M+19.9%
Rein Therapeutics Inc. logo
RNTXEmployee Related Expenses — General And Administrative Expense
$859K-9.3%

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.62B+145%
Enterprise value$1.37B+117%
P/S+1.6×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219515
Line itemBiopharmaRoyalty ManagementTotal
Total Internal R&D(2)15,3131515,328
Total R&D33,9553633,991
External G&A(3)8,7213,39812,119
Internal G&A(2)10,1353,94814,083
Total G&A18,8567,34626,202
Total operating expenses52,8117,38260,193
(Loss) income from operations(52,811)18,174(34,637)
Interest income2,3283252,653

Item 1. Consolidated Financial Statements

FAQ

What is AnaptysBio, Inc.'s internal expenses — general and administrative expense?
AnaptysBio, Inc. (ANAB) reported internal expenses — general and administrative expense of $14.08M in Q1 2026.
How has AnaptysBio, Inc.'s internal expenses — general and administrative expense changed year-over-year?
AnaptysBio, Inc.'s internal expenses — general and administrative expense increased by 63.9% year-over-year, from $8.59M to $14.08M.
What is the long-term trend for AnaptysBio, Inc.'s internal expenses — general and administrative expense?
Over 3 years (2022 to 2025), AnaptysBio, Inc.'s internal expenses — general and administrative expense has grown at a 3.8% compound annual growth rate (CAGR), from $29.36M to $32.79M.
What does internal expenses — general and administrative expense mean?
This metric captures the overhead costs associated with the internal segment, including executive compensation, legal, finance, and other corporate support functions. It represents the fixed operational costs required to maintain the company's infrastructure and administrative operations. Monitoring this helps investors assess the company's ability to manage corporate overhead relative to its clinical development progress.

Ask your AI about AnaptysBio, Inc.'s internal expenses — general and administrative expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude